

# Arne Kolstad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8473487/publications.pdf>

Version: 2024-02-01

75  
papers

2,883  
citations

331642

21  
h-index

175241

52  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2636  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. <i>Leukemia</i> , 2022, 36, 177-188.	7.2	11
2	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	1.7	1
3	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 655-666.	2.8	1
4	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	30.7	182
5	Rituximab-treated patients with lymphoma develop strong CD8 T cell responses following COVID-19 vaccination. <i>British Journal of Haematology</i> , 2022, 197, 697-708.	2.5	22
6	T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. <i>Nature Biotechnology</i> , 2022, 40, 488-498.	17.5	12
7	FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma "Are We Hitting the Target?". <i>Molecular Imaging and Biology</i> , 2022, 24, 807-817.	2.6	3
8	FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1902-1914.	6.4	6
9	A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. <i>Med</i> , 2021, 2, 180-195.e5.	4.4	0
10	Infiltration of CD163+, PD-L1+ and FoxP3+ positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. <i>British Journal of Haematology</i> , 2021, 193, 520-531.	2.5	12
11	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. <i>Cancer Reports</i> , 2021, , e1524.	1.4	1
12	Myelosuppression in patients treated with <sup>177</sup> Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. <i>Acta Oncologica</i> , 2021, 60, 1481-1488.	1.8	5
13	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	2.7	18
14	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	1.4	8
15	Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 3519-3519.	1.4	0
16	KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	3.5	96
17	p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	2.5	31
18	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	5.2	33

#	ARTICLE	IF	CITATIONS
19	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. BMC Cancer, 2020, 20, 1202.	2.6	3
20	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood, 2020, 135, 2000-2004.	1.4	26
21	Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE, 2020, 15, e0230526.	2.5	22
22	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood, 2020, 136, 36-36.	1.4	5
23	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. Blood, 2020, 136, 1-3.	1.4	18
24	Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience. Blood, 2020, 136, 8-9.	1.4	0
25	Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 27-28.	1.4	1
26	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. Blood, 2020, 136, 15-15.	1.4	7
27	Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2311-2321.	6.4	14
28	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunology Research, 2019, 7, 355-362.	3.4	82
29	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Advances, 2019, 3, 1230-1243.	5.2	43
30	A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies. Blood, 2019, 134, 1495-1495.	1.4	1
31	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. Blood, 2019, 134, 2816-2816.	1.4	14
32	ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).. Journal of Clinical Oncology, 2019, 37, TPS7573-TPS7573.	1.6	4
33	System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. Blood, 2019, 134, 2897-2897.	1.4	0
34	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematology, the, 2018, 5, e109-e116.	4.6	117
35	Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1233-1241.	6.4	21
36	Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. Hematological Oncology, 2018, 36, 217-223.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody <sup>177</sup> Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2018, 59, 704-710.	5.0	16
38	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clinical Cancer Research, 2018, 24, 870-881.	7.0	75
39	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica, 2018, 103, e541-e543.	3.5	19
40	The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. British Journal of Haematology, 2018, 183, 225-234.	2.5	24
41	LYMRIT 37-01: A Phase I/II Study of <sup>177</sup> Lu-Lilotomab Satetraxetan (Betalutin <sup>®</sup> ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) – Analysis with 6-Month Follow-up. Blood, 2018, 132, 2879-2879.	1.4	11
42	Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center Cell Populations. Cytometry Part B - Clinical Cytometry, 2017, 92, 79-87.	1.5	23
43	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq1 1 0.784314 rgBT / Over 428-435.	2.0	56
44	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood, 2017, 130, 1903-1910.	1.4	296
45	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia and Lymphoma, 2017, 58, 623-632.	1.3	5
46	Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate <sup>177</sup> Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2017, 58, 48-54.	5.0	29
47	Red Marrow <sup>177</sup> Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody <sup>177</sup> Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody <sup>177</sup> Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody <sup>177</sup> Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2017, 58, 55-61.	5.0	22
48	A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. British Journal of Haematology, 2016, 173, 432-443.	2.5	23
49	Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of T cell receptor stimulated B cells from spontaneous and DNA damage-induced apoptosis. Immunology, 2016, 149, 62-73.	4.4	5
50	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood, 2016, 128, 1814-1820.	1.4	75
51	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. British Journal of Haematology, 2016, 175, 410-418.	2.5	170
52	Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. Oncoimmunology, 2016, 5, e1138199.	4.6	6
53	Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up. Blood, 2016, 128, 1095-1095.	1.4	4
54	Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. Blood, 2016, 128, 146-146.	1.4	4

#	ARTICLE	IF	CITATIONS
55	177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. <i>Blood</i> , 2016, 128, 1780-1780.	1.4	2
56	Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 917-917.	1.4	1
57	The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177lu-Satetraxetan-Lilotomab. <i>Blood</i> , 2016, 128, 5339-5339.	1.4	0
58	Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. <i>Haematologica</i> , 2015, 100, e240-e243.	3.5	12
59	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	1.4	45
60	Computerized image analysis of the Ki67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015, 67, 62-69.	2.9	12
61	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	2.5	22
62	Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 840-847.	2.0	5
63	In situ vaccination for systemic effects in follicular lymphoma. <i>Onc Immunology</i> , 2015, 4, e1014773.	4.6	1
64	A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 8598-8598.	1.6	0
65	Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL). <i>Blood</i> , 2015, 126, 5118-5118.	1.4	0
66	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	1.4	90
67	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. <i>Blood</i> , 2014, 124, 3094-3094.	1.4	3
68	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. <i>Blood</i> , 2014, 124, 2994-2994.	1.4	0
69	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013, 122, 1768-1768.	1.4	2
70	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial. <i>Blood</i> , 2013, 122, 4377-4377.	1.4	11
71	Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients. <i>Blood</i> , 2013, 122, 4487-4487.	1.4	0
72	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	2.5	241

#	ARTICLE	IF	CITATIONS
73	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010, 115, 1530-1533.	1.4	167
74	R-CHOEP-14 Å— 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2â€™3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18â€™65 Years.. <i>Blood</i> , 2010, 116, 2805-2805.	1.4	2
75	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivoâ€™purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i> , 2008, 112, 2687-2693.	1.4	571